Medplus Health IPO: Finalization of the share allotment of MedPlus Health Services has been announced and now all eyes are on MedPlus IPO listing date, which is most likely on 23rd December 2021. public issue price 1,398.30 crore 52.59 times were subscribed in 3 days bidding from 13 to 15 December 2021. The gray market is also indicating about the book built issue after the allotment of shares. According to market observers, MedPlus Health Services shares are trading at a premium 160 in the gray market today.
Medplus IPO GMP
According to Market Observers, MedPlus IPO GMP Is Today 160, which is 25 more than yesterday’s gray market premium 135. Market observers said the MedPlus IPO subscription status book reflects investor interest in the built issue and may also reflect on the date of listing. He Said MedPlus IPO Was Slipped From GMP 220 to 135 level due to negative primary markets. Now, even after heavy selloff in Friday and Monday session, Medplus IPO GMP is today 160, which is about 20 percent more than its price band 780 to 796 per equity share. He said that in such a bearish market today Medplus Health IPO is GMP 160 means gray market is bullish on public issue even in this bearish market.
What does this GMP mean?
Market observers said the GMP is nothing but an unofficial data that helps in ascertaining the estimated listing profit from the IPO. MedPlus IPO as GMP Is Today 160, means that the gray market is expecting MedPlus Health shares to list around 956 ( 796+ 160).
However, stock market experts say that GMP is not an ideal indicator of listing premium. The financial and balance sheet of the company is a must-see as it gives a solid and clear financial position and business outlook of the company.
Highlighting the basics about MedPlus Health IPO; Abhay Doshi, Founder, UnlistedArena.com, said, “MedPlus is the second largest pharmacy retailer in terms of revenue from operations offering an omni-channel platform with over 2000 retail stores, while revenue from online sales accounts for about 9 percent of total revenue. Revenue Operations and EBITDA from Operations grew by 16.21 per cent and 63.21 per cent respectively from FY 2019-21. The performance of 6 months FY22 has also been exceptional. In the upper band, the issue is priced at around 6.8x its book value (post) -issue) and at 71.5x PE based on annual FY 2012 earnings after issue. The issue price is quite high even after considering the remarkable performance.”
Disclaimer: The views and recommendations given above are those of individual analysts or broking companies and not of Mint.
Never miss a story! Stay connected and informed with Mint.
download
Our App Now!!
,